Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Intro slide
- Neurodegenerative disorders to be discussed
- Neuropathology of neurodegeneration
- Neuropathology of ageing
- Age-associated plaques/tangles accumulation (1)
- Age-associated plaques/tangles accumulation (2)
- Neurodegenerative disorders - AD
- AD: Macroscopic pathology (1)
- AD: Macroscopic pathology (2)
- Determination of regional volumes
- Volume loss correlated to neuron loss
- Regional atrophy in AD
- AD: neuropathological diagnosis
- AD: plaques
- CERAD criteria
- AD: neurofibrillary tangles (1)
- AD: neurofibrillary tangles (2)
- Braak staging of NFTs
- NIA-Reagan Institute Criteria
- Nucleus Basalis of Meynert (NbM)
- Neuron loss in AD (1)
- Neuron loss in AD (2)
- Neurodegenerative disorders - LBD
- Lewy body diseases
- LBD: neuropathological diagnosis
- Spread of Lewy bodies: Braak Staging (1)
- Spread of Lewy bodies: Braak Staging (2)
- Regional atrophy in DLB
- DLB: other pathology
- Neurodegenerative disorders - FTD
- FTLD: macroscopic pathology (1)
- FTLD: macroscopic pathology (2)
- Regional atropy in FTLD
- FTLD: disease staging
- Tauopathy: distribution by stage (1)
- Tauopathy: distribution by stage (2)
- FTLD: neuropathological diagnosis
- FTLD: neuron loss
- Neurodegenerative disorders - HD
- Huntington's disease
- Regional atrophy in HD
- HD: macroscopic pathology
- HD: disease staging
- HD: microscopic pathology (1)
- HD: microscopic pathology (2)
- Neurodegenerative disorders - MND
- Motor Neuron Disease (1)
- Motor Neuron Disease (2)
- ALS: microscopic pathology (1)
- ALS: microscopic pathology (2)
- Conclusions
- References
- Acknowledgements
Topics Covered
- Current neuropathological diagnostic criteria for neurodegenerative disorders
- Major macroscopic and microscopic features
- Pattern and extent of brain atrophy
- Alzheimer's disease
- Lewy body diseases
- Frontotemporal dementia
- Other tauopathies
- Huntington's disease
- Motor Neurone Disease
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Kril, J. (2007, October 1). Neuropathology of neurodegenerative disorders [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/VGTL2469.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Jillian Kril has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Neuroscience
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I'm Jillian Kril,
I'm a professor of neuropathology at the University of Sydney, and
this presentation is on the neuropathology of neurodegenerative disorders.
I will describe the major pathological features of common groups of neurodegenerative diseases.
0:20
I will focus on the four main groups of
disorders that are commonly encountered in clinical practice.
These are Alzheimer's disease (AD), frontotemporal dementias (FTD),
motor neurone disease (MND/ALS), and Lewy Body diseases (LBD).
0:34
However, as these terms are often used to describe
both the clinical and the pathological entity,
I will endeavor to use 'Alzheimer's disease neuropathological change'
instead of 'Alzheimer's disease', and 'frontotemporal lobar degeneration'
0:48
instead of 'frontotemporal dementia'.
Unfortunately, there aren't different terms used for
the pathology and clinical presentations of ALS or Lewy body diseases.
In discussing each of these neuropathological disorders,
I will focus on the macroscopic features of the disease, the extent, severity,
and anatomical distribution of atrophy in particular.
This is because atrophy can be paralleled in neuroimaging, and
therefore the information that we glean from
neuropathological studies can be used to inform clinical diagnoses.
I will also look at the microscopic features,
in particular the proteinopathies that differentiate
these neurodegenerative disorders, and their cellular and anatomical distribution.
I will also examine the neuropathological diagnostic criteria for each disorder.
A few words to begin with about the assessment of atrophy in post mortem brains.
This is done quantitatively using a technique developed by my colleagues and I,
whereby we were able to differentiate precise regions of
the brain on a whole hemisphere.
Once the hemisphere is sectioned, using these markings and some anatomical landmarks,
we're able to parcellate the entire brain into different functional regions.